A trend report is the reporting of a statistically significant increase in the frequency or severity of non-serious incidents as well as expected adverse side effects of a medical device or IVD. It focuses on patterns that may affect the benefit–risk ratio, even though individual observations on their own do not trigger reporting of a serious incident. The manufacturer must detect such trends, assess them, and report them to the competent authorities.
Which observations trigger a trend
The reporting logic applies to non-serious incidents and expected adverse side effects. The increase must be statistically significant and must lead, or be capable of leading, to risks for patients, users, or other persons that are not acceptable in view of the intended benefit. Not every fluctuation in a complaints statistic therefore constitutes a trend report.
In its quality management system, the manufacturer defines how frequency and severity are monitored, against which reference population they are compared, and from when a signal is escalated. Relevant factors may include product family, market volume, duration of use, batch, software version, and severity. The methodology must be suitable to distinguish a genuine shift from random variation or merely improved data capture.
From signal to authority report
If a reportable trend is identified, the report is submitted to the competent authority of the Member State in which the incidents occurred. The analysis should describe which events were pooled, which statistical evaluation was used, and why the result may affect the benefit–risk ratio. Further steps may follow, such as a root-cause analysis, a change to risk controls, or a field safety corrective action.
A trend report does not remove the obligation to document individual cases. Individual case data in particular provide the basis for robustly assessing coding, severity, and a possible relationship to the product. For certain well-documented recurring serious incidents, the rules on periodic summary reporting may be relevant; however, this does not replace the manufacturer’s own assessment of whether a non-serious pattern must be reported as a trend.
Thresholds for a trend analysis should be defined in advance and justified transparently for the respective product group. A higher number of reported events may, for example, result from increasing sales volumes, a longer observation period, or improved capture. Only an appropriate denominator and an assessment of event severity allow a meaningful conclusion.
The results of the analysis belong in the vigilance and PMS documentation, even if a signal does not meet the reporting criteria. This makes it clear which observations were reviewed, why no trend was assumed, and when the data will be re-evaluated. This documentation makes it possible to correctly place a later accumulation of individual events in time.
For low-volume products, statistical assessment can be particularly challenging because a few cases can change the rate substantially. This does not relieve the manufacturer of signal assessment, but it does require a methodology that explicitly accounts for small datasets, clinical relevance, and uncertainty.
Distinction from individual case reporting
Individual case reporting concerns a serious incident that meets the legal criteria and is assessed directly on the basis of the specific case. Trend reporting applies where the individual events are not reportable as serious incidents or constitute expected side effects, but their accumulation or increasing severity may indicate an unacceptable risk.
Both procedures may become relevant in parallel. If non-serious malfunctions initially accumulate, trend analysis can make a deterioration visible; if a later individual case results in serious harm, it must additionally be handled under the procedure for serious incidents. Trend reporting is therefore not a substitute for case assessment, but a statistical safety view of the overall dataset.
Relevance for clinical trials
During a clinical investigation, recurring observations that are not serious in themselves may indicate a changed product profile. The safety database should therefore capture events and product deficiencies in a structured way so that clusters can be identified by investigational product version, site, user group, or time trend. A conspicuous trend may trigger an updated risk analysis, additional training, or an adjustment of monitoring at the investigational site, even if no single case justifies stopping the study.
Full-service CROs such as Mediconomics support coding conventions and analysis plans for recurring safety data, as well as alignment between clinical monitoring, data management, and vigilance. They prepare trend tables, narrative analyses, and follow-up documentation so that the sponsor can justify why a signal was assessed as random variation, a trend, or a reason for a corrective action.
Frequently Asked Questions (FAQ)
Can an expected side effect be the subject of a trend report?
Yes. A statistically significant increase in expected adverse side effects must be reported if it can materially affect the benefit–risk ratio and can lead to unacceptable risks.
Does a trend report replace reporting of a serious incident?
No. A serious incident is reported as a specific individual case in accordance with the applicable vigilance requirements.
Is an increase in the absolute number of cases sufficient for a trend report?
No. The assessment requires a statistically significant increase and must examine frequency or severity in relation to an appropriate comparator baseline.
Regulatory References
- Regulation (EU) 2017/745, Article 88 – requires reporting of significant trends for medical devices.
- Regulation (EU) 2017/746, Article 83 – contains the corresponding trend reporting obligation for IVDs.
- MDCG 2023-3 Rev.2 – distinguishes trend reports from reports of serious incidents.
- MDCG 2024-1-5 – illustrates trend reports in a product-specific vigilance guideline.